Doxecitine and Doxribtimine: First Approval

Area of Science:

• Biochemistry
• Pharmacology
• Genetics

Background:

• Thymidine kinase 2 deficiency (TK2d) is a rare mitochondrial DNA depletion disorder.
• TK2d leads to progressive multi-systemic symptoms, primarily affecting neuromuscular function.
• Current treatment options for TK2d are limited, highlighting the need for novel therapeutic strategies.

Purpose of the Study:

• To outline the key developmental milestones of doxecitine and doxribtimine.
• To detail the regulatory pathway leading to the first approval of KYGEVVI® for TK2d.
• To provide a comprehensive overview of the drug's journey from development to market.

Main Methods:

• Review of preclinical and clinical development data for doxecitine and doxribtimine.
• Analysis of regulatory submissions and approval processes.
• Summary of UCB's strategic development initiatives for KYGEVVI®.

Main Results:

• Doxecitine and doxribtimine (KYGEVVI®) demonstrated a favorable profile in clinical studies.
• The U.S. Food and Drug Administration (FDA) approved KYGEVVI® in November 2025.
• Approval covers adult and pediatric patients with TK2d with symptom onset by age 12.

Conclusions:

• The development and approval of doxecitine and doxribtimine represent a significant advancement in treating TK2d.
• KYGEVVI® offers a new therapeutic option for patients with this debilitating genetic disorder.
• This milestone underscores the importance of targeted therapies for rare genetic diseases.